These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36357397)

  • 1. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
    Cantley J; Ye X; Rousseau E; Januario T; Hamman BD; Rose CM; Cheung TK; Hinkle T; Soto L; Quinn C; Harbin A; Bortolon E; Chen X; Haskell R; Lin E; Yu SF; Del Rosario G; Chan E; Dunlap D; Koeppen H; Martin S; Merchant M; Grimmer M; Broccatelli F; Wang J; Pizzano J; Dragovich PS; Berlin M; Yauch RL
    Nat Commun; 2022 Nov; 13(1):6814. PubMed ID: 36357397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
    Reichl KD; Lee ECY; Gopalsamy A
    Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong
    Yang L; Tu W; Huang L; Miao B; Kaneshige A; Jiang W; Leng L; Wang M; Wen B; Sun D; Wang S
    J Med Chem; 2023 Aug; 66(15):10761-10781. PubMed ID: 37523716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors - a review of patent literature from 2019-June 2023.
    Lee ECY; Reichl KD; Gopalsamy A
    Expert Opin Ther Pat; 2024 Apr; 34(4):211-229. PubMed ID: 38742308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
    Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
    Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
    Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
    Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
    Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
    Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
    Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
    Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines.
    Ehrenhöfer-Wölfer K; Puchner T; Schwarz C; Rippka J; Blaha-Ostermann S; Strobl U; Hörmann A; Bader G; Kornigg S; Zahn S; Sommergruber W; Schweifer N; Zichner T; Schlattl A; Neumüller RA; Shi J; Vakoc CR; Kögl M; Petronczki M; Kraut N; Pearson MA; Wöhrle S
    Sci Rep; 2019 Aug; 9(1):11661. PubMed ID: 31406271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.
    Fernando TM; Piskol R; Bainer R; Sokol ES; Trabucco SE; Zhang Q; Trinh H; Maund S; Kschonsak M; Chaudhuri S; Modrusan Z; Januario T; Yauch RL
    Nat Commun; 2020 Nov; 11(1):5551. PubMed ID: 33144586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo.
    Kofink C; Trainor N; Mair B; Wöhrle S; Wurm M; Mischerikow N; Roy MJ; Bader G; Greb P; Garavel G; Diers E; McLennan R; Whitworth C; Vetma V; Rumpel K; Scharnweber M; Fuchs JE; Gerstberger T; Cui Y; Gremel G; Chetta P; Hopf S; Budano N; Rinnenthal J; Gmaschitz G; Mayer M; Koegl M; Ciulli A; Weinstabl H; Farnaby W
    Nat Commun; 2022 Oct; 13(1):5969. PubMed ID: 36216795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
    He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Vaishampayan U; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
    Proc Natl Acad Sci U S A; 2024 Apr; 121(15):e2322563121. PubMed ID: 38557192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutathione-dependent degradation of SMARCA2/4 for targeted lung cancer therapy with improved selectivity.
    Ji M; Yu D; Liu X; Wang L; Zhang D; Yang Z; Huang W; Fan H; Wang L; Sun H
    Eur J Med Chem; 2024 Nov; 277():116751. PubMed ID: 39128328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.
    Guerrero-Martínez JA; Reyes JC
    Sci Rep; 2018 Feb; 8(1):2043. PubMed ID: 29391527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.
    Mota M; Sweha SR; Pun M; Natarajan SK; Ding Y; Chung C; Hawes D; Yang F; Judkins AR; Samajdar S; Cao X; Xiao L; Parolia A; Chinnaiyan AM; Venneti S
    Proc Natl Acad Sci U S A; 2023 May; 120(18):e2221175120. PubMed ID: 37094128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.
    Xiao L; Parolia A; Qiao Y; Bawa P; Eyunni S; Mannan R; Carson SE; Chang Y; Wang X; Zhang Y; Vo JN; Kregel S; Simko SA; Delekta AD; Jaber M; Zheng H; Apel IJ; McMurry L; Su F; Wang R; Zelenka-Wang S; Sasmal S; Khare L; Mukherjee S; Abbineni C; Aithal K; Bhakta MS; Ghurye J; Cao X; Navone NM; Nesvizhskii AI; Mehra R; Vaishampayan U; Blanchette M; Wang Y; Samajdar S; Ramachandra M; Chinnaiyan AM
    Nature; 2022 Jan; 601(7893):434-439. PubMed ID: 34937944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
    Jelinic P; Schlappe BA; Conlon N; Tseng J; Olvera N; Dao F; Mueller JJ; Hussein Y; Soslow RA; Levine DA
    Mod Pathol; 2016 Jan; 29(1):60-6. PubMed ID: 26564006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian high-grade serous carcinoma cells with low SMARCA4 expression and high SMARCA2 expression contribute to platinum resistance.
    Kido K; Nojima S; Motooka D; Nomura Y; Kohara M; Sato K; Ohshima K; Tahara S; Kurashige M; Umeda D; Takashima T; Kiyokawa H; Ukon K; Matsui T; Okuzaki D; Morii E
    J Pathol; 2023 May; 260(1):56-70. PubMed ID: 36763038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.